Photo from wikipedia
The beneficial effects of biologic disease‐modifying anti‐rheumatic drugs (bDMARDs), such as tumour necrosis factor inhibitors (anti‐TNF) in active ankylosing spondylitis (AS) are well established. The significant costs on patients in… Click to show full abstract
The beneficial effects of biologic disease‐modifying anti‐rheumatic drugs (bDMARDs), such as tumour necrosis factor inhibitors (anti‐TNF) in active ankylosing spondylitis (AS) are well established. The significant costs on patients in the absence of financial subsidization can limit their use. The objective was to describe a consensus development process on recommendations for government‐assisted funding of biologic therapy for AS patients in Singapore.
Keywords:
modifying anti;
anti rheumatic;
ankylosing spondylitis;
consensus development;
disease modifying;
biologic disease
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!